260 Charles Street Waltham MA 02453 USA [t] 001 781 296 2500 [f] 001 781 296 2550
Decision Resources is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
Decision Resources finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents will be used for first line treatment of multiple sclerosis.
Market analyst, Decision Resources has found that a therapy's effect on incidence of mortality at 30 days is the attribute that most influences surveyed cardiologists' prescribing decisions in non-ST elevation myocardial infarction (NSTEMI).
Decision Resources anticipates five percent annual growth through 2017 in the ulcerative colitis drug market will be driven by strong uptake of Abbott/Eisai's Humira, Centocor/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's golimumab and Bristol-Myers Squibb's Orencia, following the expected approvals and launches of these three biologic agents for ulcerative colitis by 2017.
